Endothelial dysfunction, hypertension and atherosclerosis: A review of the effects of lacidipine

被引：16

作者：

Haller H. ^{[1
]}

Cosentino F. ^{[1
]}

Luscher T.F. ^{[1
]}

机构：

[1] Cardiology Cardiovascular Center, Univ. Hosp./Cardiovascular Research, Institute of Physiology, University of Zurich, Zurich

来源：

Drugs in R & D | 2002年 / 3卷 / 5期

关键词：

Calcium Antagonist; Intracellular Reactive Oxygen Species; Isradipine; Adhesion Molecule Expression; Lacidipine;

D O I：

10.2165/00126839-200203050-00005

中图分类号：

学科分类号：

摘要：

Lacidipine, a third generation dihydropyridine calcium antagonist, has demonstrated pronounced anti-atherosclerotic activity in preclinical studies. The drug can act at several stages within the atherosclerotic process, utilising its anti-hypertensive and antioxidant properties to protect hypertensive animals against mortality and vascular damage, to reduce cholesterol levels from the vessel wall of hypercholesterolaemic animals, and to reduce the progression of existing atherosclerotic lesions. The clinical benefit of lacidipine in atherosclerosis has recently been confirmed in humans in a large, multicentre, comparative, 4-year clinical trial involving patients with mild to moderate hypertension. The European Lacidipine Study on Atherosclerosis (ELSA) showed that lacidipine was able to slow the progression of atherosclerosis, measured as carotid intimato-media thickness, by 40% compared with atenolol (p = 0.0073). Although further comparative trials are needed, based on the results of ELSA, lacidipine is likely to become a promising therapeutic agent for atherosclerosis.

引用

页码：311 / 323

页数：12

共 57 条

[1]

Reichardt B., Holzgreve H., Antiatherosclerotic effects of lacidipine, Rev. Contemp. Pharmacother., 6, pp. 37-43, (1995)

[2]

Bond M.G., Purvis C., Mercuri M., Antiatherogenic properties of calcium antagonists, J. Cardiovasc. Pharmacol. Ther., 17, pp. S87-S93, (1991)

[3]

Tulenko T., Laury-Kleintop L., Walter M., Et al., Cholesterol, calcium and atherosclerosis: Is there a role for calcium channel blockers in atheroprotection?, Int. J. Cardiol., 62, pp. S55-S66, (1997)

[4]

Weinstein D.B., Heider J.G., Protective action of calcium antagonists in atherosclerosis and experimental vascular injury, Am. J. Hypertens., 2, pp. 205-212, (1989)

[5]

Luscher T.F., Cosentino F., The classification of calcium antagonists and their selection in the treatment of hypertension. A reappraisal, Drugs, 55, pp. 509-517, (1998)

[6]

Herbette L.G., Mason P.E., Gaviraghi G., Et al., The molecular basis for lacidipine's unique pharmacokinetics: Optimal hydrophobicity results in membrane interactions that may facilitate the treatment of atherosclerosis, J. Cardiovasc. Pharmacol., 23, pp. S16-S25, (1994)

[7]

Luscher T.F., The endothelium in hypertension: Bystander, target or mediator?, J. Hypertens., 12, pp. S105-S116, (1994)

[8]

Ross R., Atherosclerosis -an inflammatory disease, N. Engl. J. Med., 340, pp. 115-126, (1999)

[9]

Eickelberg O., Roth M., Block L.-H., Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: Implications for vascular protection, Int. J. Cardiol., 62, pp. S31-S37, (1997)

[10]

Libby P., Sukhova G., Lee R.T., Et al., Molecular biology of atherosclerosis, Int. J. Cardiol., 62, pp. S23-S29, (1997)

← 1 2 3 4 5 6 →